You are here: Industry Insights > Seattle Genetics

News List

PADCEV succeeds in confirmatory phase 3 trial in urothelial cancer pharmaceutical-business-review
September 23, 2020
Seattle Genetics and Astellas Pharma said that PADCEV (enfortumab vedotin-ejfv) met the primary endpoint of overall survival (OS) in a confirmatory phase 3 trial in previously treated locally advanced or metastatic urothelial cancer.
MSD partners with Seattle Genetics on two new oncology projects pharmatimes
September 16, 2020
MSD, known as Merck in the US and Canada, has announced two new oncology collaborations with biotech company and oncology specialist Seattle Genetics.
Merck to acquire $1bn equity stake in Seattle Genetics pharmaceutical-technology
September 16, 2020
Drugmaker Merck is acquiring a $1bn equity stake in Seattle Genetics as part of oncology collaborations with the company.
Seattle Genetics and Merck Partner contractpharma
September 15, 2020
Seattle Genetics Inc. and Merck, known as MSD outside the United States and Canada, have announced two new strategic oncology collaborations.
Seattle Genetics gets approval of TUKYSA in Switzerland for metastatic HER2-positive breast cancer pharmaceutical-business-review
May 15, 2020
Seattle Genetics announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for TUKYSA (tucatinib) tablets in combination with trastuzumab and capecitabine, for the treatment of patients with metastatic HER2-positive breast
Seattle Genetics gets FDA nod for breast cancer drug Tukysa pharmaceutical-business-review
April 22, 2020
Seattle Genetics has secured approval from the US Food and Drug Administration (FDA) for its Tukysa (tucatinib) to treat people with advanced unresectable or metastatic HER2-positive breast cancer.
Seattle Genetics, Astellas gets USFDA priority review for Enfortumab Vedotin biospectrumasia
September 18, 2019
The filing is based on results from the first cohort of patients in the EV-201 pivotal phase 2 clinical trial that were presented as a late-breaking oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2019.
Astellas, Seattle Genetics Announce BLA Submission for Enfortumab Vedotin americanpharmaceuticalreview
July 17, 2019
Astellas Pharma and Seattle Genetics announced submission of a Biologics License Application for accelerated approval to the U.S. Food and Drug Administration for the investigational agent enfortumab vedotin for the ...
Seattle Genetics CEO goes inside its lightning-quick Adcetris nod, courtesy of FDA's real-time pilot fiercepharma
December 05, 2018
Seattle Genetics CEO Clay Siegall remembers reading about the first FDA approvals under the agency’s new Real Time Oncology Review pilot, secured 24 and 28 days after filing.
Seattle Genetics CEO goes inside its lightning-quick Adcetris nod, courtesy of FDA's real-time pilot fiercepharma
December 05, 2018
SAN DIEGO—Seattle Genetics CEO Clay Siegall remembers reading about the first FDA approvals under the agency’s new Real Time Oncology Review pilot, secured 24 and 28 days after filing.

Previous page 1 2 Next page